Relapsed childhood cancers show genomic scars left by previous therapy
Ranking
Overall
73
Content
85
Popularity
46
Observed public metrics from 1 member.
Merged summary
TL;DR - Whole-genome sequencing reveals that childhood cancer therapies, particularly platinum-based treatments, can rapidly leave distinctive DNA-damage patterns in relapsed tumors. These signatures correlate with worse outcomes and could help monitor relapse and inform treatment.
- The study analyzed hundreds of childhood tumors, emphasizing pretreated, relapsed, and metastatic samples.
- Previous therapies were associated with rapid acquisition of characteristic mutational signatures.
- Platinum-based treatments produced especially notable genomic scars.
- Therapy-linked signatures could serve as biomarkers for relapse tracking and clinical decisions.
Sources (1)
Relapsed childhood cancers show genomic scars left by previous therapy
Public signals
OpenAlex citations 0
TL;DR - Whole-genome sequencing reveals that childhood cancer therapies, particularly platinum-based treatments, can rapidly leave distinctive DNA-damage patterns in relapsed tumors. These signatures correlate with worse outcomes and could help monitor relapse and inform treatment.
- The study analyzed hundreds of childhood tumors, emphasizing pretreated, relapsed, and metastatic samples.
- Previous therapies were associated with rapid acquisition of characteristic mutational signatures.
- Platinum-based treatments produced especially notable genomic scars.
- Therapy-linked signatures could serve as biomarkers for relapse tracking and clinical decisions.